Atorvastatin (Lipitor)
Sponsors
University of Oslo School of Pharmacy, University of Chicago, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., The Cleveland Clinic, Brooke Army Medical Center
Conditions
Aortic Valve StenosisCardiovascular DiseaseCerebrovascular AccidentCoronary ArteriosclerosisDiabetes Mellitus, Type 2DyslipidemiaEnd-Stage Kidney DiseaseGraves Ophthalmopathy
Phase 1
Phase 4
Association Between Systemic Exposure of Atorvastatin and Metabolites and Atorvastatin-induced Myotoxicity
CompletedNCT00120055
Start: 2005-02-28End: 2005-04-30Updated: 2014-12-03
Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets
CompletedNCT00442325
Start: 2003-01-31End: 2004-02-29Target: 595Updated: 2021-02-18
Establish The Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST)
CompletedNCT00442845
Start: 2003-01-31End: 2004-02-29Target: 2080Updated: 2021-02-18
The Effect of Lipitor on Aortic Stenosis
TerminatedNCT00590135
Start: 2000-08-31End: 2010-04-26Updated: 2017-07-26
Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba
CompletedNCT00926614
Start: 2008-09-30End: 2011-12-31Updated: 2012-02-14
Dyslipidemia in Cardiovascular Disease
CompletedNCT01029522
Start: 2008-08-31End: 2009-11-30Updated: 2012-08-09
The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia
CompletedNCT01285544
Start: 2008-09-30End: 2009-07-31Updated: 2013-12-17